<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485274</url>
  </required_header>
  <id_info>
    <org_study_id>SToP-C</org_study_id>
    <nct_id>NCT03485274</nct_id>
  </id_info>
  <brief_title>Substance Misuse To Psychiatric Disorders for Cannabis</brief_title>
  <official_title>Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses
      amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy
      intervention study to offer an evidence-based strategy aiming to stop individuals with
      cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic
      disabling dependence or co-morbid state.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomised single-blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>treatment in each intervention arms is masked to the outcome assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in severity of Cannabis Use Disorder (CUD)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in severity of the cannabis use disorder for the 2 arms as defined by DSM-5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prevalence of Cannabis induced mood disorder</measure>
    <time_frame>6 months</time_frame>
    <description>The prevalence of the cannabis induced disorder in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton anxiety (HAM-A) rating scale</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change of anxiety severity of the two treatment arms using HAM-A for both treatment arms with cut-off of defining anxiety &gt;=14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton depression (HAM-D) rating scale</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change of depression severity of the two treatment arms using HAM-D for both treatment arms with cut-off of defining depression &gt;=8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive outcome</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change in cognitive outcome using Frontal Assessment Battery in the two treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <condition>Depressive State</condition>
  <condition>Anxiety State</condition>
  <condition>Depression</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Pharmacotherapy</condition>
  <arm_group>
    <arm_group_label>Vortioxetine Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral: 5-20mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any medication or Rx other than vortixoetine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>oral medication taken once daily</description>
    <arm_group_label>Vortioxetine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <description>Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine</description>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive
        cannabis test results in 1 month with anxiety or depressive symptoms

        Exclusion Criteria:

          -  Age &lt;16 years old

          -  Unable to read English or Chinese

          -  Unable to give informed consent

          -  Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation

          -  Had history of primary psychotic episode

          -  Had been diagnosed to have substance-induced mood disorder, other than cannabis

          -  Had been diagnosed to have mood disorders or anxiety disorders

          -  Had been taking maintenance therapeutic dose of antidepressant continuously &gt;= 6
             months AND with depressive symptom or anxiety symptom being in remission

          -  Had known hypersensitivity to vortioxetine

          -  Had known history of serotonin syndrome

          -  Pregnant

          -  Mother currently breast-feeding

          -  Currently taking warfarin and/or having poorly controlled bleeding disorder

          -  Had history of prolonged QTc ≥500ms and/or known unstable or untreated cardiology
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert KK Chung, MBBS(HK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert KK Chung, MBBS(HK)</last_name>
    <phone>2255 4486</phone>
    <email>chungkka@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albert KK Chung, MBBS</last_name>
    <email>stop.hku@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert KK Chung</last_name>
      <phone>2255 3067</phone>
      <email>chungkka@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Albert Kar-Kin Chung</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <keyword>medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

